Drug Use-Results Survey of Erbitux (Injection 100 mg) for EGFR-Positive, Curatively Unresectable Advanced or Recurrent Colorectal Cancer Patients

Drug Use-Results Survey of Erbitux (Injection 100 mg) for EGFR-Positive, Curatively Unresectable Advanced or Recurrent Colorectal Cancer Patients - Drug Use-Results Survey of Erbitux (mCRC)

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033658

Enrollment

1800

Registered

2018-08-08

Start date

2009-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR-Positive, Curatively Unresectable Advanced or Recurrent Colorectal Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who were administrated Erbitux for patient with EGFR-Positive, Curatively Unresectable Advanced or Recurrent Colorectal Cancer (mCRC).

Exclusion criteria

Exclusion criteria: Patients who do not give a full consent to this survey.

Design outcomes

Primary

Measure	Time frame
(Safety) 1-1. Profile of ADRs/infections reported (types, grades, and incidence rates, etc.) 1-2. Factors potentially affecting the safety of Erbitux (analyzing the types and incidence rates of ADRs/infections by patient demographic and baseline characteristics)	—

Secondary

Measure	Time frame
(Effectiveness) 1. Factors potentially affecting the effectiveness of Erbitux (analyzing the effective rate by patient demographic and baseline characteristics)	—

Countries

Japan

Contacts

Public ContactHiroshi Suzuka

Merck Serono Co., Ltd. PMS Planning & Strategy, Medical Department

hiroshi.suzuka@merckgroup.com03-6756-0837

Outcome results